Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

Aethlon Medical (AEMD) Gains from Sales and Divestitures (2017 - 2025)

Aethlon Medical filings provide 7 years of Gains from Sales and Divestitures readings, the most recent being $12707.0 for Q1 2025.

On a quarterly basis, Gains from Sales and Divestitures fell 63.04% to $12707.0 in Q1 2025 year-over-year; TTM through Mar 2025 was $12707.0, a 63.04% decrease, with the full-year FY2025 number at $12707.0, down 63.04% from a year prior.
Gains from Sales and Divestitures hit $12707.0 in Q1 2025 for Aethlon Medical, down from $76943.0 in the prior quarter.
In the past five years, Gains from Sales and Divestitures ranged from a high of $76943.0 in Q4 2024 to a low of $12707.0 in Q1 2025.